Zilucoplan
Immune ModulationresearchAlso known as: Zilucoplan
A macrocyclic peptide complement C5 inhibitor approved for myasthenia gravis. Represents a new class of peptide-based complement inhibitors.
Overview
A macrocyclic peptide complement C5 inhibitor approved for myasthenia gravis. Represents a new class of peptide-based complement inhibitors. This peptide represents an important class in the therapeutic peptide landscape and is included in Peptide Playbook for comprehensive education.
Mechanism of Action
See summary for primary mechanism. Detailed pharmacology available in referenced studies.
Molecular Formula
See literature
Molecular Weight
See literature
Sequence
See literature
Dosage Protocols
Dose Range
Varies – Varies
Frequency
Per protocol
Route
varies
Cycle Length
Per protocol
Dosing must be determined by a licensed healthcare provider based on individual assessment.
Source: Clinical literature
🧮 Personalized Dosage Calculator
💰 Estimated Pricing
Typical Supply
Prefilled syringes
Last Updated
2026-02
Specialty drug for myasthenia gravis. Insurance/copay assistance required.
⚠️ Prices are estimates based on publicly available data and may vary significantly by vendor, location, and prescription status. This is not medical or financial advice.
Side Effects
| Effect | Severity |
|---|---|
| varies |
Pros & Cons
Research-backed therapeutic compound
Specific mechanism of action
Clinical data available
Part of growing peptide therapeutics field
May require prescription
Individual response varies
Not all uses FDA-approved
Requires medical supervision
Research Studies
🩸 Blood Work
No specific bloodwork requirements reported for this peptide. General health panels are always recommended before starting any peptide protocol.
Legal Status
Varies by jurisdiction. Consult local regulations and healthcare provider.
Readers Also Viewed
Semaglutide
99An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.
BPC-157
98A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.
Tirzepatide
97A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.
CJC-1295 + Ipamorelin (Combo)
95The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.
Related Peptides
CJC-1295 + Ipamorelin (Combo)
The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.
Ipamorelin
A highly selective growth hormone-releasing peptide (GHRP) that stimulates GH release with minimal impact on cortisol, prolactin, or appetite, making it the cleanest GHRP available.
MK-677 (Ibutamoren)
An orally active, non-peptide growth hormone secretagogue that mimics ghrelin to raise GH and IGF-1 levels for up to 24 hours per dose, with notable effects on sleep, appetite, and body composition.
CJC-1295 (no DAC) / Mod GRF 1-29
A modified growth hormone-releasing hormone fragment with a short half-life (~30 minutes) that stimulates pulsatile growth hormone release, closely mimicking the body's natural GH secretion pattern.